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Abstract Arginine adenosine-50-diphosphoribosylation
(ADP-ribosylation) is an enzyme-catalyzed, potentially
reversibleposttranslationalmodiﬁcation,inwhich theADP-
ribose moiety is transferred from NAD
? to the guanidino
moiety of arginine. At 540 Da, ADP-ribose has the size of
approximately ﬁve amino acid residues. In contrast to
arginine, which, at neutral pH, is positively charged, ADP-
ribose carries two negatively charged phosphate moieties.
Arginine ADP-ribosylation, thus,causesanotablechange in
size and chemical property at the ADP-ribosylation site of
thetargetprotein.Often,thiscausesstericinterferenceofthe
interaction of the target protein with binding partners, e.g.
toxin-catalyzed ADP-ribosylationofactinatR177 sterically
blocks actin polymerization. In case of the nucleotide-gated
P2X7 ion channel, ADP-ribosylation at R125 in the vicinity
of the ligand-binding site causes channel gating. Arginine-
speciﬁc ADP-ribosyltransferases (ARTs) carry a character-
istic R-S-EXE motif that distinguishes these enzymes from
structurally related enzymes which catalyze ADP-ribosyla-
tion of other amino acid side chains, DNA, or small mole-
cules. Arginine-speciﬁc ADP-ribosylation can be inhibited
by small molecule arginine analogues such as agmatine or
meta-iodobenzylguanidine (MIBG), which themselves can
serve as targets for arginine-speciﬁc ARTs. ADP-ribosy-
larginine speciﬁc hydrolases (ARHs) can restore target
protein function by hydrolytic removal of the entire
ADP-ribose moiety. In some cases, ADP-ribosylarginine is
processed into secondary posttranslational modiﬁcations,
e.g. phosphoribosylarginine or ornithine. This review
summarizes current knowledge on arginine-speciﬁc ADP-
ribosylation, focussing on the methods available for its
detection, its biological consequences, and the enzymes
responsible for this modiﬁcation and its reversal, and dis-
cusses future perspectives for research in this ﬁeld.
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Introduction
ADP-ribosylation of arginine is a reversible posttransla-
tional modiﬁcation (PTM) of proteins in which the ADP-
ribose moiety is transferred from NAD
? to the guanidino
group of arginine under release of nicotinamide (Fig. 1).
This reaction is catalyzed by a subfamily of ADP-ribo-
syltransferases (ARTs) that bind NAD
? in an extended
conformation, enabling the nucleophilic attack of one of
the two terminal nitrogen atoms of the guanidino group of
arginine on the b-N-glycosidic bond between nicotinamide
and the C10-atom of the ribose-group (Haag and Koch-
Nolte 1997; Jacobson and Jacobson 1989; Margarit et al.
2006; Moss and Vaughan 1990; Tsuge et al. 2008). Nico-
tinamide is released and a new N-glycosidic bond between
arginine and ADP-ribose is generated with an inversion of
the conformation at the C10 atom of ADP-ribose from beta
to alpha (Fig. 1). Arginine ADP-ribosylation can be fully
reversed by speciﬁc enzymes (ADP-ribosylhydrolases).
Other acceptor amino acids, such as diphthamide (a mod-
iﬁed histidine), cysteine or asparagine, are targeted by
other sub-families of ADP-ribosyltransferases via a similar
reaction mechanism (Berti et al. 1997; Hottiger et al. 2010;
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Methods for detecting arginine ADP-ribosylation
Several NAD
? analogues have been employed to visualize
arginine ADP-ribosylation. Using radioactively labelled
[
32P]-NAD
? as a substrate, radiolabelled target proteins
can be detected by SDS-PAGE autoradiography (Fig. 2)
(Koch-Nolte et al. 1996; Vandekerckhove et al. 1987;
Zolkiewska and Moss 1993). In a similar way, the use of
biotinylated NAD
? or etheno-NAD
? (an NAD
? analogue
with an additional penta-ring, i.e. etheno-group, on the
adenosine moiety) allows detection of the target protein by
western blot analyses using streptavidin or the etheno-
adenosine-speciﬁc monoclonal antibody 1G4, respectively
(Krebs et al. 2003). These NAD-analogues can be used also
to detect ADP-ribosylated proteins on the surface of intact
cells by ﬂow cytometry. However, they do not allow the
detection of endogenously ADP-ribosylated proteins and
do not provide information on the identity of the acceptor
amino acid.
Several attempts have been made to generate antibodies
that recognize ADP-ribosylated arginine residues, analo-
gous to those that have been used for detecting phospho-
tyrosine or phospho-serine residues (Meyer and Hilz 1986;
Osago et al. 2008; Schwab et al. 2000). Most of the anti-
bodies described so far, however, lack speciﬁcity for
arginine ADP-ribose, i.e. show cross reactivity with other
mono- or poly-ADP-ribosylated amino acid residues.
Similarly, a naturally occurring ADP-ribose-binding
domain has been used to detect and purify ADP-ribosylated
proteins. This domain was found to bind to proteins ADP-
ribosylated on arginine and other amino acid residues
(Dani et al. 2009).
Fig. 1 Schematic diagram of
the enzyme catalyzed,
reversible posttranslational
modiﬁcation of arginine by
ADP-ribose. In the active centre
of an ADP-ribosyltransferase
(ART), NAD
? is brought into
an extended conformation that
permits the attack of the target
arginine on the b-N-glycosidic
bond between nicotinamide and
the C10-atom of the ribose
group. This leads to the
formation of ADP-
ribosylarginine with C10 in
a-conformation, while
nicotinamide is released. The
native arginine can be recovered
by the reverse reaction,
catalyzed by an ADP-
ribosylarginine hydrolase
(ARH). This enzyme hydrolyses
the a-glycosidic bond, releasing
ADP-ribose
HEK-cell lysates
autoradiograph
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Fig. 2 Monitoring ADP-ribosylation by speciﬁc and promiscuous
ARTs by SDS-PAGE autoradiography. HEK-cell lysates were
incubated for 10 min at 37C with arginine-speciﬁc ARTs (ART2.2,
SpvB, C2) or non-arginine-speciﬁc ARTs (C3stau2, C3bot, PT) in the
presence of [
32P]-NAD
?. Proteins were size-fractionated by SDS-
PAGE and visualized by Coomassie staining (a). SDS-resistant, i.e.
covalently incorporated, radioactivity was detected by autoradiogra-
phy (b). While most bacterial ARTs modify a single prominent band,
mouse ART2.2 (lane 1) modiﬁes many target proteins. Enzymes used
for ADP-ribosylation: Mouse ART2.2 (ART2); Salmonella enterica
SpvB toxin (SpvB); Clostridium botulinum C2 toxin (C2); Staphylo-
coccus aureus exoenzyme C3stau2 (C3stau); Clostridium botulinum
C3 toxin (C3bot); Pertussis toxin (PT)
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123ADP-riboslyation of arginine can be distinguished from
that at other amino acid residues by its higher sensitivity to
hydrolysis by hydroxylamine (Cervantes-Laurean et al.
1993), or by arginine-speciﬁc ADP-ribosylhydrolase
ARH1 (see below). Moreover, ADP-ribosylation of argi-
nine can be blocked by arginine analogues such as agma-
tine or meta-iodobenzylguanidine (MIBG) that function as
competitive inhibitors (Fig. 3). Both, agmatine and MIBG,
can themselves be ADP-ribosylated by arginine-speciﬁc
ARTs, a reaction that can be monitored by thin layer
chromatography and autoradiography (Koch-Nolte et al.
1996; Loesberg et al. 1990).
Speciﬁc ADP-ribosylated arginine residues can be iden-
tiﬁed bymass spectrometry(MS) and/orsequencing.To this
end, the puriﬁed ADP-ribosylated protein is subjected to
protease digestion. The resulting peptides are fractionated
by high-performance liquid chromatography (HPLC) and
subsequently identiﬁed by Edman sequencing or MS
(Margarit et al. 2006; Paone et al. 2002; Pope et al. 1985;
Terashima et al. 1992; Zhou et al. 1996). Recently, two new
techniques have been developed to facilitate the identiﬁca-
tion of target residues by MS. In one approach, the frag-
mentation of ADP-ribose-containing tryptic peptides
generates characteristic breakdown products of ADP-ribose
or ADP-ribosylarginine that can be used to trace the ADP-
ribosylated peptides (Hengel et al. 2009; Osago et al. 2009).
In a second approach, tryptic fragments containing ADP-
ribosemoietieswerespeciﬁcallyenrichedusingatitanoxide
afﬁnity matrix before MS analysis (Lang et al. 2010).
Speciﬁc ADP-ribosylated arginine residues have also
been identiﬁed successfully by site-directed mutagenesis
followed by an ADP-ribosylation assay, e.g. in transfected
cells or with puriﬁed proteins (Adriouch et al. 2008;
Ganesan et al. 1998; Ganesan et al. 1999a; Hochmann et al.
2006; Lupi et al. 2000).
Structural and functional consequences of arginine
ADP-ribosylation
Arginine ADP-ribosylation causes a notable change in size
and chemical property at the ADP-ribosylation site of the
target protein. While the average size of one amino acid is
approximately 110 Da, the attached ADP-ribose group is a
large bulky group that is nearly ﬁve times as big (approx.
540 Da). In contrast to arginine, which, at neutral pH, is
positively charged, ADP-ribose carries two negatively
charged phosphate moieties. Thus, the attachment of ADP-
ribose results in a relatively large increase in molecular
weight and in the introduction of two new negative charges
to the acceptor molecule. By comparison, phosphorylation
leads to an increase of approximately 80 Da and to the
introduction of a single additional negative charge.
ADP-ribosylation at arginine residues can affect the
function of target proteins by different mechanisms and the
resulting effect on protein function can be activating or
inactivating.Inprinciple,theintroductionofthebulkyADP-
ribose moiety could sterically block the interaction with a
binding partner, create a new docking site for ADP-ribose
binding domains in other proteins, or induce a conforma-
tionalchange.Stericblockade isexpectedtobeinactivating,
whereas the creation of interaction sites with molecular
partners or the induction of a conformational change will
often be activating, as in case of phosphorylation.
Steric hindrance has been shown by X-ray crystallog-
raphy to be the mechanism by which the ADP-ribosylation
of G-actin at Arg177 inhibits actin polymerisation (Marg-
arit et al. 2006). Steric hindrance has also been implicated
in the reduced binding of the small G protein ras to its
guanine nucleotide exchange factor Cdc25 upon ADP-
ribosylation of ras at Arg41 (Ganesan et al. 1999b), and in
altered DNA recognition by E. coli RNA polymerase upon
Fig. 3 Schematic diagrams of
molecules relevant to ADP-
ribosylation. a–c Target amino
acids with a terminal nitrogen
group that can be modiﬁed by
non-arginine speciﬁc ARTs;
d–f guanidino group-containing
targets of arginine-speciﬁc
ARTs; g, h products of
enzymatic and non-enzymatic
hydrolysis of ADP-ribosylated-
arginine. a lysine; b asparagine;
c glutamine; d arginine;
e agmatine; f MIBG (meta-
iodobenzylguanidine);
g ornithine; h phospho-
ribosylarginine
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123ADP-ribosylation at Arg265 (Depping et al. 2005; West-
blade et al. 2008).
ADP-ribosylation can also result in the creation of
molecular interaction sites. The macro module found in the
histone macroH2A1.1 and several other proteins is an
ADP-ribose binding domain (Till and Ladurner 2009).
An archaebacterial macro domain has been used success-
fully in pulldown experiments to purify arginine ADP-
ribosylated proteins (Dani et al. 2009). While histone
macroH2A1.1 has recently been shown to bind to poly-
ADP-ribosylated nuclear proteins in live cells (Timinszky
et al. 2009), it remains to be determined whether arginine-
ADP-ribosylated proteins similarly interact with macro
domains or other protein modules in vivo.
The mostthoroughlystudied examplefor the activation of
atargetproteinbytheinductionofaconformationalchangeis
the gating of the P2X7 ion channel by ADP-ribosylation
(Seman et al. 2003). P2X7 is an adenosine-50-triphosphate
(ATP) gated cation channel expressed on haematopoietic
cells that mediates a multitude of pro-inﬂammatory effects.
Triggering of P2X7 by its soluble ligand, ATP, causes an
inﬂuxofcalciumandanefﬂuxofpotassiumions,resultingin
membrane changes (externalisation of phosphatidylserine,
blebbing) and, ultimately, in cell death by apoptosis. Acti-
vation of P2X7 generally requires high (upper micromolar
range) concentrations of extracellular ATP. However, on
naive murine T lymphocytes, which carry ART2.2, P2X7 is
activated by low micromolar concentrations of extracellular
NAD
? via ADP-ribosylation on Arg 125 (Adriouch et al.
2008;Schwarzetal.2009).Thisleadstorapidapoptoticdeath
of naı ¨ve T lymphocytes carrying ART2.2, a phenomenon
termedNAD-induced cell death (NICD) (Semanetal.2003).
Ithasbeenproposedthatthisprovidesspacefortheexpansion
of activated effector T cells, which are rendered resistant to
NICD upon shedding of ART2.2 (Koch-Nolte et al. 2006).
ART2-deﬁcient mice (Ohlrogge et al. 2002) are viable
and fertile, but are resistant to NICD (Adriouch et al. 2008;
Seman et al. 2003). Depending on the expression levels of
ART2.2 and on other factors, different T cell subpopula-
tions show varying degrees of sensitivity to NICD. Thus, in
a mouse model for insulin-dependent type 1 diabetes
(T1D), the absence of ART2 leads to the enhanced survival
of a population of invariant Natural Killer-T (iNKT) cells
that exert a negative regulatory inﬂuence on disease pro-
gression. Here, genetic deletion or pharmacological
blockade of ART2 are associated with a decreased inci-
dence of the disease (Scheuplein et al. 2010).
Scope of arginine ADP-ribosylation
HowmanydifferenttargetproteinscanbemodiﬁedbyADP-
ribosylation? This questionis difﬁcultto answer,but several
lines of evidence indicate that the target proteins identiﬁed
to date represent only the tip of an iceberg. In principle,
the scope of arginine ADP-ribosylation is determined by the
relativelocationofARTsandtheirtargetproteins,andbythe
local availability of the substrate NAD
?. The concentration
of NAD
? is two to three orders of magnitude higher in the
intracellular than in the extracellular compartment. All
vertebrate ARTs identiﬁed to date are membrane-bound or
secreted ectoenzymes with the capacity to modify several
different proteins (promiscuous), while most bacterial toxin
ARTs affecting vertebrate organisms act inside the cell and
modify only a single target (monospeciﬁc) (Koch-Nolte
et al. 2008). The incubation of intact mouse T lymphocytes
(that carry cell-surface ART2) withradioactive NAD results
in the labelling of numerous bands, of which onlya minority
has been identiﬁed. Although no intracellular arginine-
speciﬁc ARTs have been characterized to date, arginine
ADP-ribosylation of intracellular proteins including Gb,
actin, and histones has been detected by biochemical means
(Corda and Di Girolamo 2003). Little is known about the
availability of NAD
? in different subcellular compartments,
but an elegant recent study using poly ADP-ribose polymers
generated by poly-ADP-ribosylpolymerase-1 (PARP-1) tar-
geted to different cellular compartments provided evidence
for distinct NAD
? pools in mitochondria, peroxisomes, and
in the ER and Golgi (Dolle et al. 2010). In addition to cell-
surfaceandintracellularsubstrates,itisatpresentimpossible
to estimate the scope of secreted soluble proteins such as
cytokines(Saxtyet al. 2001) or defensins(Paoneet al.2002)
that may serve as targets for ADP-ribosylation.
A better assessment of the scope of endogenously ADP-
ribosylated target proteins should become possible with
improvements of afﬁnity isolation techniques for purifying
arginine-ADP-ribosylated proteins before analysis by mass
spectrometry. The ﬁnding that arginine-speciﬁc ADP-ri-
bosyltransferases can employ etheno-NAD or biotin-NAD
as substrates opens the possibilities of using immobilized
monoclonal antibody 1G4 directed against etheno-adeno-
sine or immobilized avidin to afﬁnity purify etheno-ADP-
ribosylated or biotin-ADP-ribosylated target proteins,
respectively (Krebs et al. 2003). Similarly, immobilized
macro-domains may be suited to purify the proteome of
ADP-ribosylated target proteins (Dani et al. 2009). Neither
of these procedures, however, is speciﬁc for arginine-ADP-
ribosylation. This bottleneck might be surmounted only
with novel afﬁnity puriﬁcation tools based on ADP-ribosyl-
arginine speciﬁc antibodies.
Arginine-speciﬁc ADP-ribosyltransferases
Arginine residues are ADP-ribosylated by arginine-speciﬁc
ADP-ribosyltransferases (ARTs). These enzymes represent
260 S. Laing et al.
123a well-characterized subfamily of the larger family of
structurally related proteins that includes ARTs which
ADP-ribosylate other amino acid residues, DNA, tRNA and
antibiotics (Koch-Nolte et al. 2008). On the basis of the
constellation of amino acid residues at three positions
essential for NAD-binding, ARTs can be divided into two
major subclasses, ARTC (Cholera toxin-like) carrying the
R-S-E triad motif and ARTD (Diphtheria toxin-like) carry-
ing the H-Y-E triad motif (Hottiger et al. 2010). Arginine-
speciﬁc ARTs belong to the ARTC subclass and can be
distinguished from other members of this subclass on the
basisofacharacteristicvariantR-S-EXEtriadmotif(Fig. 4).
Arginine-speciﬁc ARTs have been isolated and molecularly
characterizedfromphages,bacteriaandvertebrates(Table 1).
Target arginines have been identiﬁed in numerous target
proteins. In many but not all cases, the responsible ARTs
have been identiﬁed by molecular cloning.
Factors determining the speciﬁcity of certain ARTs
for arginine
The factors determining the speciﬁcity of arginine-speciﬁc
ARTs are still poorly understood. In addition to their target
proteins, many arginine-speciﬁc ARTs can also ADP-
ribosylate poly-L-arginine and small arginine-analogues
that contain a guanidino group such as agmatine or MIBG
(Fig. 3). However, they do not ADP-ribosylate other ter-
minal nitrogen-containing amino acid side chains such as
asn, gln or lys, which do serve as targets for other ARTs
(e.g. C. botulinum C3, P. luminescence TccC5, and human
PARP-1, respectively) (Altmeyer et al. 2009; Lang et al.
2010; Sekine et al. 1989).
Severallinesofevidenceindicatethatargininespeciﬁcity
is governed by a glutamic acid residue at the edge of the
catalytic cleft. This acidic amino acid residue is positioned
two amino acids upstream of the catalytic glutamic acid and
deﬁnes the variant R-S-EXE triad motif (Koch-Nolte et al.
2008). Figure 4 shows ﬁve examples, where pairs of closely
related ARTs differ at this position. In each case only the
EXE containing ART modiﬁes arginine. Cholera toxin
(EXE) ADP-ribosylates Gas at Arg187, whereas the related
pertussis toxin (QXE) ADP-ribsylates Gai at cysteine
(Corda and Di Girolamo 2003). MTX (EXE) ADP-ribosy-
lates elongation factor Tu and other proteins on arginine, the
related pierisin (QXE) ADP-ribosylates guanosine in DNA
(Carpusca et al. 2006). C2 and SpvB (EXE) ADP-ribosylate
actin at Arg177 (Aktories et al. 1986; Margarit et al. 2006;
Vandekerckhoveetal.1988),therelatedC3enzymes(QXE)
ADP-ribosylate rho at asparagine 41 (Aktories and Barth
2004; Sekine et al. 1989). Mouse ART2 (EXE) ADP-ri-
bosylates P2X7 at Arg125 and Arg133 and other proteins at
arginine residues (Adriouch et al. 2008; Koch-Nolte et al.
1996), rat ART2 (QXE) does not modify target proteins but
hydrolyzes NAD
? to ADP-ribose and nicotinamide (Haag
etal.1995).ChickenART4 (EXE) modiﬁes several proteins
at arginine residues; human ART4 (KXE) does not display
anydetectableARTactivity(Glowackietal.2002;Grahnert
et al. 2008). Direct experimental evidence for the impor-
tance of the EXE-motif was provided by site directed
mutagenesis of ART2 and C3, in which creating or dis-
rupting this motif conferred or destroyed the ability to ADP-
ribosylate arginine residues (Hara et al. 1996; Maehama
et al. 1996; Vogelsgesang and Aktories 2006).
Factors determining the preference of promiscuous
ARTs for certain arginines
It is a striking observation that some arginine-speciﬁc
ARTs show a high degree of speciﬁcity for a certain target
ARTT loop
…
 KLYRADSR  46  GYV STSLS  39  PHPD EQEVSALG   CT
 RLYRADSR  46  GYVSTSLS  40  PHPY EQEVSALG   LT
 RLLRWDRR  37  IFVSTTRA  44  PFPN EDEITFPG   MTX
 IAYRRVDG  41  SFSSTSLK  30  GFQD EQEILLNK   C2
 TVYRRSGP  35  NFISTSIG  31  GYAG EYEVLLNH   CDT
 IVYRRSGP  35  NFISTSIG  31  GYAG EYEVLLNH   Iota
 VVYRGLKL  22  AFM STSPD  26  HFKG EAEMLFPP   SpvB
 TVYRWCGM  29  GYMSTSLS  31  GFAS EKEILLDK   VIP2
 KTFRGTRG  16  GYL STSLN  27  NYKN EKEILYNK   ExoS
 KTFRGTQG  16  GYL STSRD  28  IEGD EQEILYDK   ExoT
QVFRGVHG  15  GFA SASLK  27  FFPGEEEVLIPP   hART1
 LVYRGTKV  13  QFSSSSLT  31  SFPREEEVLIPG   mART2.2
 RVHRGVKD  14  RFTSTSRL  27 YYTSEKEVLIPP   chART4
VVFRGVGS  15  QFASSSLD  27 VFPKEREVLIPP   hART5
 TVYRYDSR  35  AFVSTSSS  66  LATYQSEYLAHR   PT
 RLVRWDRR  36  IFVSTTKT  40  PWPNQMEVAFPG   pierisin
 YVYRLLNL  45  GYSSTQLV  31  AYPGQQEVLLPR   C3stau2
 SVYRGTKT  13  QFTSSSLS  31  FRPDQEEVLIPG   rART2
 VHYRTKDV  13  QFLSTSLL  24  YFSLKKEVLIPP   hART4
 SSYHGTKP  25  KGFYSTDN  83  EGSSSVEYINNW   DT      
 LLWHGSRT  26  KGIYFADM  81  TCLLYN EYIVYD   chPARP1
β1 β2 β5
R-S-E
H-Y-E
arg-
specific 
ARTs
Fig. 4 Sequence alignment of arginine- and non-arginine-speciﬁc
ARTs. The regions surrounding the three catalytically important
residues on the b1, b2, and b5 strands are aligned (Hottiger et al.
2010; Koch-Nolte et al. 2001; Otto et al. 2005). The R-S-E and H-Y-E
motifs characterizing the major ART families are highlighted in
yellow. For the R-S-E ARTs, the residue in position -2 relative to the
catalytic glutamic acid in b5 is highlighted in grey. Speciﬁcity for
arginine is determined by the presence of glutamic acid at this
position (R-S-EXE motif). Enzymes shown in the alignment: cholera
toxin (CT); Escherichia coli heat labile enterotoxin (LT); Bacillus
sphaericus mosquitocidal toxin (MTX); Clostridium botulinum C2
toxin (C2); Clostridium difcile ADP-ribosylating toxin (CDT);
Clostridium perfringens iota toxin (Iota); Salmonella enterica SpvB
toxin (SpvB); Bacillus cereus VIP2 toxin (VIP2); Pseudomonas
aeruginosa exoenzyme S (ExoS); Pseudomonas aeruginosa exoen-
zyme T (ExoT); human ART1 (hART1); mouse ART2.2 (mART2.2);
chicken ART4 (chART4); human ART5 (hART5); pertussis toxin
(PT); Pieris rapae pierisin-1 (pierisin); Staphylococcus aureus
exoenzyme C3stau2 (C3stau2); rat ART2 (rART2); human ART4
(hART4); diphtheria toxin (DT); chicken poly(ADP-ribose)transfer-
ase-1 (chPARP-1). Underlined sequences indicate residues conﬁrmed
to be in b-strands in the respective crystal-structures. The ARTT
(ADP-ribosyltransferase turn-turn) loop is involved in target protein
recognition and contributes to catalysis (Koch-Nolte et al. 2001;
Menetrey et al. 2008)
ADP-ribosylation of arginine 261
123protein, while others are capable of modifying many dif-
ferent targets. ARTs such as SpvB and C2 ADP-ribosylate
only a speciﬁc target protein at a speciﬁc arginine residue,
i.e. actin at Arg177 (Fig. 2, lanes 3 and 4). Other ARTs
appear more promiscuous, e.g. mouse ART2, which ADP-
ribosylates many proteins, albeit only at arginine residues
(Fig. 2, lane 1). However, even in the case of this ‘‘pro-
miscuous’’ ART, the identiﬁcation of two speciﬁc arginine
residues in the target protein P2X7 shows that only certain
arginine residues are chosen for modiﬁcation, i.e. Arg125
and Arg133, but not 16 other arginine residues exposed on
the surface of the protein (Fig. 5). This raises the question
of what governs the selection of target proteins, and within
them, of target residues? Target speciﬁcity is presumably
regulated on several levels.
InthecaseofthespeciﬁcARTs,targetspeciﬁcityislikely
determined by structural complementarity between the
enzymeanditstarget.Intherecentlyelucidated3Dstructure
of co-crystallized Clostridium perfringens iota toxin and
actin, ﬁve loops in the toxin ﬂanking the NAD-binding
crevice interact substantially with actin (Tsuge et al. 2008).
Thetargetarginine177ofactintherebyispositionedcloseto
the ﬁrst glutamate residue of the EXE motif. It is reasonable
to assume that other speciﬁc ARTs such as DRAT, T4 and
CT undergo similar extensive interactions with their target
proteins. The EXE motif is contained within a prominent
loop, designated ADP-ribosyltransferase turn turn or ARTT
loop, preceding and including the catalytic glutamic acid
residue (Fig. 4) (Han and Tainer 2002; Koch-Nolte et al.
2001). This loop has been shown to participate in target
recognition also in the 3D structures of other distantly
related ARTs with their targets, including PARP-1 and
ADP-ribose (Ruf et al. 1998), rifampin ADP-ribosyltrans-
ferase and rifampin (Baysarowich et al. 2008), and Pseu-
domonas aeruginosa exotoxin A (ETA) and elongation
factor 2 (Jorgensen et al. 2008).
In the case of the promiscuous ARTs, binding of target
proteins evidently is much less stringently controlled by
surface complementarity. Nevertheless, the ARTT loop
seems to play a certain role also in target selection by the
Table 1 Arginine-speciﬁc ARTs and their target speciﬁcities
Enzyme Speciﬁcity
a Target(s) Residue(s)
b Reference(s)
Microbial
E.coli T-phages toxins (ALT/MOD) p RNA-polymerase and others R265 (Goff 1974; Depping et al. 2005)
Rhodospirillum rubrum DRAT s Dinitrogenase reductase R101 (Pope et al. 1985; Ludden 1994)
Vibrio Cholerae toxin (CT) s Gas,G at R187 (Moss et al. 1977; Spangler 1992)
Escherichia coli toxin (LT1/LT2) s Gas,G at R187 (Moss et al. 1979; Spangler 1992)
Bacillus sphaericus toxin (MTX) p EF-Tu and others Unknown (Schirmer et al. 2002)
Clostridium botulinum toxin (C2) s Actin R177 (Aktories et al. 1986; Vandekerckhove
et al. 1988)
Clostridium difﬁcile toxin (CDT) s Actin R177 (Stubbs et al. 2000)
Clostridium perfringens iota toxin s Actin R177 (Vandekerckhove et al. 1987; Boquet
et al. 1998)
Salmonella enterica toxin (SpVB) s Actin R177 (Tezcan-Merdol et al. 2001; Margarit
et al. 2006)
Bacillus cereus toxin (VIP2) s Actin R177 (Han et al. 1999)
Pseudomonas exotoxin S (ExoS) p ras and others R41/R128 (Ganesan et al. 1998)
Pseudomonas exotoxin T (ExoT) p Crk and others Unknown (Sun and Barbieri 2003)
Vertebrate
ART1 p a7 integrin,
HNP-1 and others
Unknown
R14/R24
(Zolkiewska and Moss 1993; Paone et al.
2002; Paone et al. 2006)
ART2.1/ART2.2 p P2X7 and others R125/R133 (Seman et al. 2003; Adriouch et al. 2008)
Turkey erythrocyte ART p Actin R95, R372 (Just et al. 1995)
Chicken heterophil ART p Tuftsin, actin and others R4
R28, R206
(Terashima et al. 1995; Terashima
et al. 1997)
Rabbit muscle cell ART p Desmin R48, R62 (Huang et al. 1993; Zhou et al. 1996)
Chinese hamster ART p Gb R129 (Lupi et al. 2000)
Hen liver nuclear ART p Kemptide R2, R3 (Matsuura et al. 1988)
a Speciﬁc (s) or promiscuous (p)
b Preferred sites are in bold
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123more promiscuous ARTs. The ART domains of exotoxins
S and T of P. aeruginosa are closely related, yet differ in
speciﬁcity for target molecules. Barbieri and coworkers
elegantly demonstrated that speciﬁcity for target proteins
could be transferred by grafting deﬁned loops from one
enzyme onto the other (Sun et al. 2004). In the case of
these promiscuous ARTs and the closely related vertebrate
ARTs, other factors such as cellular compartmentalization
and topological constraints presumably regulate accessi-
bility of arginine residues in target proteins. In this respect,
promiscuous ARTs resemble certain protein kinases which
are promiscuous toward a wide range of artiﬁcial sub-
strates, but nevertheless exhibit a certain degree of target
speciﬁcity in vivo (Woodgett et al. 1986).
A ﬁrst level of speciﬁcity is achieved by regulation of the
access of the enzyme to the target molecule. The plasma
membrane and intracellular membranes present natural
barriersthatcouldrestricttheaccessofARTstotheirtargets.
Exoenzymes S and T (ExoS and exoT) of Pseudomonas
aeruginosa are injected into the cytosol of eukaryotic cells
by the type III secretion apparatus of P. aeruginosa. These
enzymes thus may have access mainly to cytosolic proteins
(Barbieri and Sun 2004). Conversely, most of the known
vertebrate arginine-speciﬁc ARTs are anchored in the outer
leaﬂet of the plasma membrane by covalent linkage to gly-
sosylphosphatidylinositol (GPI) (Glowacki et al. 2001).
These ecto-enzymes thus may have access only to the ecto-
domains of other membrane-associated or secreted proteins.
Moreover,theGPIanchorgovernsassociationofARTswith
specialized membrane microdomains,designated lipidrafts,
which may further restrict the access of these enzymes to
otherraft-associatedproteins(Bannasetal.2005).However,
it is conceivable that ecto-ARTs may translocate across the
membrane and thereby gain access to cytosolic targets such
as Gb, which is ADP-ribosylated at Arg129 (Lupi et al.
2000). An additional level of speciﬁcity may be provided by
the topological constraint of the membrane anchor, which
may allow access of the ART only to those arginine residues
of its target that are at the same distance from the membrane
asthecatalyticsite.Thishasbeenhypothesizedtodetermine
the choice of target residues modiﬁed by ART1 in integrin
a7 (Zolkiewska 2005).
It is conceivable that the accessibility of arginine resi-
dues for ADP-ribosylation is inﬂuenced also by the con-
formation of the target protein and/or its interaction with
other proteins. Integrins and other identiﬁed targets of
membrane anchored ARTs, for example, are known to
undergo large conformational alterations, e.g. after binding
Fig. 5 Three-dimensional
models of P2X7 (a), ras (b), and
HNP-1 (c), highlighting
arginine residues that are targets
for ADP-ribosylation. Preferred
(primary) ADP-ribosylation
sites are highlighted in blue,
secondary target residues in
cyan. Other arginine residues
that are not targets for ADP-
ribosylation are shown in black.
Two views of each molecule,
rotated as indicated by the
arrow, are shown. The
representations were made
using the PyMol Molecular
Viewer software and are based
on the following structures in
the PDB database: 2KHT (HNP-
1) and 121P (ras). For P2X7,
arginine residues were projected
onto the recently solved
structure of zebraﬁsh P2X4
(PDB: 3I5D)
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123to ligands on other cells. Such conformational rearrange-
ments conceivably could uncover or hide particular argi-
nine ADP-ribosylation sites (Zolkiewska 2005). Moreover,
binding of the target protein to other interaction partners
may sterically interfere with access of ARTs to potential
target arginines. This has been demonstrated, for example,
in the case of antibodies that sterically interfere with ADP-
ribosylation of LFA-1 (Nemoto et al. 1996) and P2X7 (our
own observations).
Promiscuous ARTs often modify their target molecules
at more than one site, but seem to show preference for
certain sites (Table 1). These sites often are modiﬁed
preferentially or exclusively at low concentrations of the
substrate NAD
?. Elevation of the substrate concentration
may lead to the modiﬁcation at additional sites, some-
times changing the biological consequences of ADP-
ribosylation. An example is the modiﬁcation of integrin
a7 by ART1. At low concentrations of NAD
?, integrin a7
is modiﬁed exclusively within the stalk region of the
molecule, leading to an increased binding to its substrate
laminin. At higher concentrations of NAD
?, integrin a7i s
additionally modiﬁed within the ligand-binding region,
which inhibits binding to laminin (Zhao et al. 2005;
Zolkiewska 2005). Moreover, ADP-ribosylation at one
site may inﬂuence the accessibility of other arginines in
the same protein for ADP-ribosylation. For example, ras
is ADP-ribosylated by exoS preferentially at R41 but also
at R128. When both sites are mutated to lysine, a third
site R135 is ADP-ribosylated (Ganesan et al. 1998;
Ganesan et al. 1999a).
Crystal structures of ART target proteins allow a com-
parison of the location and structural contexts of arginines
that serve as targets versus those that do not. Figure 5
illustrates the location of the preferred and secondary ADP-
ribosylation sites on P2X7, ras, and human neutrophil
peptide-1 (HNP-1). HNP-1, a small secretory protein of 30
amino acids, is preferentially modiﬁed by human ART1 on
R14 with an additional site at R24 (Paone et al. 2006;
Paone et al. 2002; Stevens et al. 2009). Mouse P2X7 is
modiﬁed by ART2.2 at R125 and at R133 (Adriouch et al.
2008) (Fig. 5). Of note, in both of these cases as well as in
the case of the preferred site in HNP-1, the modiﬁed
arginine is part of a di-arginine (RR) motif. In two of these
sites (HNP-1 R14 and P2X7 R133) the ﬁrst arginine within
the motif is the acceptor, whereas in P2X7 R125 the second
arginine is modiﬁed. The artiﬁcial substrate kemptide, a
synthetic heptapeptide (L-R-R-A-S-L-G) also contains two
consecutive arginines that are the target sites for ADP-
ribosylation by both, bacterial and eukaryotic ARTs
(Kharadia and Graves 1987; Matsuura et al. 1988). Inter-
estingly, when kemptide is modiﬁed by cholera toxin, the
ﬁrst arginine is the preferred modiﬁcation site (Kharadia
and Graves 1987), whereas when kemptide is modiﬁed by
hen liver ART, the second arginine within the motif is the
preferred modiﬁcation site (Matsuura et al. 1988). How-
ever, ART1 and ART2 can also modify single arginines,
i.e. that are not part of a di-arginine motif (Paone et al.
2006) (and our own unpublished observations). Thus, for
promiscuous arginine-speciﬁc ARTs, the target arginines
identiﬁed so far are not located within any evident common
sequence or structural motif.
Reversion of arginine ADP-ribosylation
Like many posttranslational modiﬁcations with regulatory
functions, mono-ADP-ribosylation of arginine is a poten-
tially reversible process. Examples have been reported for
both, complete removal of ADP-ribose and restoration of
protein function, as well as for the processing of ADP-
ribosylarginine to other PTMs (Fig. 6).
Complete removal of ADP-ribose
Full restoration of protein function by complete removal of
the ADP-ribose moiety is illustrated by the ADP-ribosyl-
ation cycle described in the bacterium Rhodospirillum
rubrum. These photosynthetic bacteria use reversible ADP-
ribosylation to regulate nitrogen metabolism (Ludden
1994). In conditions of darkness or ammonium saturation,
an ADP-ribosyltransferase (dinitrogenase reductase ADP-
ribosyltransferase, DRAT) is activated to ADP-ribosylate
dinitrogenase reductase at Arg101, leading to the inacti-
vation of this key enzyme of nitrogen ﬁxation. Under
conditions of light, an ADP-ribosyl-arginine hydrolase
(dinitrogenase reductase ADP-ribosylhydrolase, DRAG) is
activated that removes the regulatory ADPR moiety,
regenerating and reactivating the unmodiﬁed enzyme
(Fig. 1). A homologue of DRAG, ADP-ribosylhydrolase-1
(ARH1; gene name ADPRH) was identiﬁed in mammals
Fig. 6 Enzymatic and non-enzymatic processing of ADP-ribosylarg-
inine. See text for details. ARH ADP-ribosylhydrolase, PDE
phosphodiesterase
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123(Moss et al. 1988). It is expressed in the cytoplasm and has
the same enzymatic activity as DRAG, i.e. it removes
ADP-ribose from modiﬁed arginine residues. As ARH1 is
localized in the intracellular compartment and the known
arginine-speciﬁc ARTs in mammals modify extracellular
proteins, ecto-ARTs and ARH1 could function as partners
in ADP-ribosylation cycles only if at least one of these
proteins could translocate across the membrane. Of note,
the b-subunit of heterotrimeric G proteins (G) is ADP-
ribosylated on Arg129 by an as yet uncharacterized ART,
and is de-ADP-ribosylated by a cytosolic hydrolase, pro-
viding an example for an ADP-ribosylation cycle in
mammalian cells (Lupi et al. 2000). It has been suggested
that ARH1 may also reverse ADP-ribosylation of proteins
targeted by arginine-speciﬁc bacterial ARTs. Consistent
with this hypothesis, cells from ARH1-deﬁcient mice were
found to be more susceptible to the cytotoxic effects of
cholera toxin (Kato et al. 2007).
Processing of ADP-ribosyl-arginine
Partial reversal of extracellular arginine ADP-ribosylation
reactions may result from the action of extracellular
phosphodiesterases that cleave adenosine-50-monophos-
phate (AMP) from ADP-ribose, leaving phosphoribose
attached to the target arginine. This has been described for
the a7 integrin on skeletal muscle cells (Zolkiewska and
Moss 1995). This modiﬁcation removes the bulk of the
ADP-ribose moiety, possibly relieving steric hindrance.
However, the phosphoribose moiety still contains a nega-
tive charge and precludes re-ADP-ribosylation of the target
protein at that residue.
A second possibility for reverting arginine ADP-ribo-
sylation has recently been described for HNP-1, i.e. the
non-enzymatic hydrolysis at the guanidino carbon, result-
ing in replacement of ADP-ribosylarginine by ornithine
(Stevens et al. 2009). This modiﬁcation also precludes
re-ADP-ribosylation at this site.
Interestingly, these ‘‘secondary’’ modiﬁcations of ADP-
ribosylated arginine residues create new posttranslational
modiﬁcations in their own right. However, it remains to be
determined what effects, if any, the decoration of a protein
with a phosphoribose moiety or the replacement of arginine
with ornithine has on the function of the protein.
Interaction of arginine-ADP-ribosylation
with other PTMs
Many proteins carry multiple posttranslational modiﬁca-
tions. This is exempliﬁed by P2X7 and HNP-1, the targets
of ADP-ribosylation discussed above. Posttranslational
modiﬁcations described in the literature for the two
proteins are summarized in Table 2. In addition to ADP-
ribosylation at Arg125 and Arg133, P2X7 is glycosylated
at various asparagine residues in the extracellular domain,
and may be subject to intracellular tyrosine phosphoryla-
tion (Kim et al. 2001) and/or palmitoylation at different
residues within the C-terminal cytoplasmic tail (Gonnord
et al. 2009). HNP-1 is synthesized as a prepropeptide of 94
amino acids, which is processed via several proteolytical
cleavage steps to the functional ﬁnal peptide, which con-
tains the 30 C-terminal amino acids. The peptide is also a
substrate for phosphorylation on tyrosine 21 of the mature
peptide (Rikova et al. 2007). In addition, ADP-ribosylated
arginine at position 14 may be replaced by ornithine
(Stevens et al. 2009).
Individual PTMs may exert effects on protein function
on their own, but they can also interact to modulate protein
function. An example is given by P2X7. The localization of
this receptor to lipid rafts is controlled by palmitoylation
within the C-terminal cytoplasmic tail of the receptor
(Gonnord et al. 2009). The recruitment of the receptor to
lipid rafts, in turn, determines its accessibility to ADP-
ribosylation by ART2, and thus its activation via extracel-
lular NAD
?. ADP-ribosylation of arginines may inﬂuence
other posttranslational modiﬁcations of target proteins.
Thus, proteolytic cleavage by trypsin is blocked at arginine
residues modiﬁed by ADP-ribosylation (Paone et al. 2002;
Westblade et al. 2008).
Perspectives
The molecular characterization of enzymes catalyzing
arginine ADP-ribosylation and the identiﬁcation of target
proteins constitute important advances in the understanding
of this posttranslational modiﬁcation. Delineating the scope
of this modiﬁcation and its functional consequences in vivo
remain major challenges. Several recent technological
advances should facilitate this objective in the coming
years. Improved tools for the detection of ADP-ribosylated
proteins in complex biological mixtures, such as body
ﬂuids or cell lysates, include recombinant macro-domains
(Dani et al. 2009; Till and Ladurner 2009) and antibodies
speciﬁc for ADP-ribosyl arginine (Meyer and Hilz 1986;
Osago et al. 2008; Schwab et al. 2000). Improved tech-
niques for enriching ADP-ribosylated peptides and for
detecting ADP-ribosylated residues will facilitate identiﬁ-
cation of novel target proteins by mass spectrometry
(Hengel et al. 2009; Lang et al. 2010; Osago et al. 2009).
Furthermore, improved structure–function prediction
algorithms may allow the identiﬁcation of new ARTs,
including novel pathogen-associated toxins (Fieldhouse
and Merrill 2008). Finally, the development of speciﬁc
inhibitors of arginine ADP-ribosylation, such as the
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123blocking single-domain antibodies (nanobodies) against
ART2.2 and the Salmonella virulence protein SpvB (Koch-
Nolte et al. 2007; Wesolowski et al. 2009) open new
avenues to probe the functional role of this modiﬁcation in
vivo, and may open new therapeutic options for the treat-
ment of inﬂammatory and toxin-mediated diseases.
Conclusions
Arginine ADP-ribosylation is a posttranslational modiﬁ-
cation that introduces a large, bulky group carrying two
negative charges onto the target protein. This modiﬁcation
can affect protein functions by sterically blocking inter-
actions with partner molecules, by inducing conforma-
tional changes, or by creating docking sites for new
interaction partners. Enzymes catalyzing this reaction
have been described in phages, bacteria, and vertebrates,
but seem to be lacking in plants, insects, worms, yeast
and other unicellular eukaryotes. Arginine-speciﬁc ARTs
are characterized by the R-S-EXE signature motif of
catalytically important amino acid residues. Like other
PTMs affecting protein function, arginine-speciﬁc ADP-
ribosylation is potentially reversible. ADP-ribosylarginine
speciﬁc hydrolases (ARHs) can restore target protein
function by hydrolytic removal of the entire ADP-ribose
moiety. In some cases, ADP-ribosylarginine can be pro-
cessed into secondary PTMs, e.g. phosphoribosylarginine
or ornithine, whose functional signiﬁcance has yet to be
determined.
ADP-ribosylation is but one example of how post-
translational modiﬁcations can profoundly affect the
function of proteins. In the era of microarray technology, it
is increasingly important to recognize that knowledge of
gene expression levels alone is insufﬁcient to characterize
the functional roles of proteins within a given biological
context, e.g. a disease process (Jungblut et al. 2008; Sch-
luter et al. 2009). Beyond the description of any individual
modiﬁcation, however, the interplay between different
posttranslational modiﬁcations also should be taken into
account.
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